Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesTamoxifen and arrhythmia
Medical Oncology, 10/28/09
Slovacek L et al. – Tamoxifen is an orally active selective estrogen receptor modulator that is used in the treatment of breast cancer and is currently the world’s largest selling drug for that purpose. Long–term data from clinical trials have failed to demonstrate a cardioprotective effect and beneficial effects on serum lipid profiles. Arrhythmia secondary to tamoxifen is very rare.
Related Articles
Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: Results of a large observational study
Annals of Oncology, 10/29/09
Relevance Score: 94%
Tamoxifen-induced adduct formation and cell stress in human endometrial glands
Drug Metabolism and Disposition, 10/09/09
Relevance Score: 91%
Randomized Biomarker Trial of Anastrozole or Low-Dose Tamoxifen or Their Combination in Subjects with Breast Intraepithelial Neoplasia
Clinical Cancer Research, 11/06/09
Relevance Score: 89%
Original contribution: association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen
JAMA, 10/07/09
Relevance Score: 89%
Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen
Cochrane Reviews, 10/09/09
Relevance Score: 88%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer
Cancer, 11/25/09
Incidence of oral mucositis, its treatment and pain management in patients receiving cancer treatment at Radiation Oncology Departments in Spanish hospitals (MUCODOL Study)
Clinical and Translational Oncology, 11/25/09
Hemorrhagic Gastritis and Duodenitis Following Celiac Plexus Neurolysis
Pain Physician, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor